Ipamorelin
Phase I TrialsAlso known as: NNC 26-0161
Educational Content Only
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The FDA has not evaluated many of the peptides discussed here. Always consult a licensed healthcare provider before making any health decisions.
Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist studied for its ability to stimulate pulsatile growth hormone release with reportedly high specificity and minimal effects on cortisol or prolactin in preclinical studies.
The following areas have been examined in research contexts. This does not constitute medical advice or imply proven efficacy in humans.
- Muscle Recovery & Repair
- Growth Hormone Regulation
- Sleep Optimization
- Fat Loss & Metabolism
- Anti-Aging & Longevity
Acts as a selective agonist at the GH secretagogue receptor (GHSR-1a), stimulating growth hormone release from the pituitary. Research suggests it may have a favorable selectivity profile compared to other GHSRs.
Has completed Phase I safety trials. Not FDA-approved for general use. Often studied in combination with GHRH analogues like CJC-1295.
Selected peer-reviewed papers from research literature. These are educational references only and do not imply proven efficacy or safety in humans.
- Ipamorelin, the first selective growth hormone secretagogue
Raun K et al. (1998). European Journal of Endocrinology.DOI: 10.1530/eje.0.1390552
- Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males
Sinha DK et al. (2020). Translational Andrology and Urology.DOI: 10.21037/tau.2019.11.30
Want to learn more?
Ask Research Chat about IpamorelinHalf-Life
~2 hours
Administration
subcutaneous injection
Legal Status (US)
Research chemical in the US. Not FDA-approved for human use outside of clinical trials.
94 indexed research passages
Related Peptides
GHRP-2 (pralmorelin) is a synthetic hexapeptide and potent growth hormone secretagogue studied for its ability to stimulate pulsatile GH release through the ghrelin receptor. It has been investigated in clinical studies and is sometimes used diagnostically for growth hormone deficiency assessment in some countries.
Hexarelin is a synthetic hexapeptide and potent growth hormone secretagogue studied for its ability to stimulate GH release and its potential cardioprotective effects in animal models and early human studies.
IGF-1 (insulin-like growth factor 1) is an endogenous polypeptide hormone critical for growth, development, and metabolic homeostasis. It is produced primarily in the liver in response to GH signaling and acts through IGF-1 receptors on virtually all tissues. Recombinant IGF-1 (mecasermin) is FDA-approved for children with severe primary IGF-1 deficiency.
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of the full 44-amino acid GHRH sequence with a trans-3-hexenoic acid modification to improve stability. It is FDA-approved for reduction of excess abdominal fat (lipodystrophy) in HIV-infected patients receiving antiretroviral therapy, and has been studied for cognitive function in aging.